Literature DB >> 20404126

Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.

Lisa M Oppegard1, Kathryn R Streck, Jonathan D Rosen, Heidi A Schwanz, Karl Drlica, Robert J Kerns, Hiroshi Hiasa.   

Abstract

Bacterial resistance presents a difficult issue for fluoroquinolone treatment of bacterial infections. In previous work, we reported that 8-methoxy-quinazoline-2,4-diones are active against quinolone-resistant mutants of Escherichia coli. Here, we demonstrate the activity of a representative 8-methoxy-quinazoline-2,4-dione against quinolone-resistant gyrases. Furthermore, 8-methoxy-quinazoline-2,4-dione and other diones are shown to inhibit Staphylococcus aureus gyrase and topoisomerase IV with similar degrees of efficacy, suggesting that the diones might act as dual-targeting agents against S. aureus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404126      PMCID: PMC2897325          DOI: 10.1128/AAC.00190-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The bacteria fight back.

Authors:  Gary Taubes
Journal:  Science       Date:  2008-07-18       Impact factor: 47.728

2.  3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.

Authors:  Edmund L Ellsworth; Tuan P Tran; H D Hollis Showalter; Joseph P Sanchez; Brian M Watson; Michael A Stier; John M Domagala; Stephen J Gracheck; E Themis Joannides; Martin A Shapiro; Steve A Dunham; Debra L Hanna; Michael D Huband; Jeffrey W Gage; Joel C Bronstein; Jia Yeu Liu; Dai Q Nguyen; Rajeshwar Singh
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

3.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex.

Authors:  H Hiasa; M E Shea
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

5.  Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.

Authors:  B Fournier; X Zhao; T Lu; K Drlica; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.

Authors:  Michael D Huband; Michael A Cohen; Margaret Zurack; Debra L Hanna; Laura A Skerlos; Mark C Sulavik; Glenn W Gibson; Jeffrey W Gage; Edmund Ellsworth; Michael A Stier; Stephen J Gracheck
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

7.  Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.

Authors:  Jacob Strahilevitz; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 9.  Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.

Authors:  Juan-Pablo Caeiro; Paul B Iannini
Journal:  Expert Rev Anti Infect Ther       Date:  2003-10       Impact factor: 5.091

10.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more
  18 in total

1.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

2.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

3.  The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone.

Authors:  Sarah R C Lentz; Pratik R Chheda; Lisa M Oppegard; Tyrell R Towle; Robert J Kerns; Hiroshi Hiasa
Journal:  Biochimie       Date:  2019-02-11       Impact factor: 4.079

4.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

5.  Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site.

Authors:  Lisa M Oppegard; Heidi A Schwanz; Tyrell R Towle; Robert J Kerns; Hiroshi Hiasa
Journal:  Biochim Biophys Acta       Date:  2015-12-23

6.  Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.

Authors:  Tyrell R Towle; Chaitanya A Kulkarni; Lisa M Oppegard; Bridget P Williams; Taylor A Picha; Hiroshi Hiasa; Robert J Kerns
Journal:  Bioorg Med Chem Lett       Date:  2018-03-30       Impact factor: 2.823

7.  Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.

Authors:  Muhammad Malik; Kevin R Marks; Arkady Mustaev; Xilin Zhao; Kalyan Chavda; Robert J Kerns; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

8.  Quinazoline-2,4(1H, 3H)-diones inhibit the growth of multiple human tumor cell lines.

Authors:  Xiaoli Zhou; Xilei Xie; Gang Liu
Journal:  Mol Divers       Date:  2013-01-26       Impact factor: 2.943

9.  Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.

Authors:  Katie J Aldred; Tim R Blower; Robert J Kerns; James M Berger; Neil Osheroff
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-20       Impact factor: 11.205

10.  Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.

Authors:  Katie J Aldred; Erin J Breland; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.